natgillin/translations-raw huggingface dataset:
The European Commission granted a marketing authorisation valid throughout the European Union, for Eurican Herpes 205 to Merial on 26 March 2001. 
Euroopa Komisjon väljastas Eurican Herpes 205 müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Merial 26. märtsil 2001.
In the study to show the protection of puppies (from vaccinated bitches) from canine herpes virus, over 80% of the pups from the vaccinated bitches survived.. 
Uuringus, millega tõendati (vaktsineeritud emaste koerte) kutsikate kaitstust koerte herpesviiruse vastu, jäi ellu üle 80% vaktsineeritud emaste koerte kutsikatest.
The last one has demonstrating that induction of antibodies is equivalent when bitches are vaccinated the day of heat or 7-10 days after mating. 
Viimase uuringuga tõendati, et antikehi tekib ühtmoodi olenemata sellest, kas emaseid koeri vaktsineeritakse innapäeval või 7 -10 päeva pärast paaritust.
Eurican Herpes 205 has been studied in three laboratory studies and two field trials. 
Eurican Herpes 205-t uuriti kolmes labori- ja kahes väliuuringus.
Eurican Herpes 205 contains mineral oil. 
Eurican Herpes 205 sisaldab mineraalõli.
Eurican Herpes 205 is intended to protect the puppies from this infection during the first few days of life. 
Eurican Herpes 205 on ette nähtud kutsikate kaitsmiseks selle infektsiooni eest nende esimestel elupäevadel.
In the other, a study was made of the effect of vaccination on the ability of bitches to breed in an infected kennel. 
Teises uuringus vaadeldi vaktsineerimise mõju emaste koerte võimele nakatunud kennelis poegi saada.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) EURICAN HERPES 205 EPAR summary for the public 
EUROOPA AVALIK HINDAMISARUANNE EURICAN HERPES 205 Kokkuvõte üldsusele
Eurican Herpes 205 contains the active substance canine herpes virus (F205 strain) antigens in a dose of 0.3 to 1.75 µg. 
Eurican Herpes 205 sisaldab toimeainena koerte herpesviiruse (F205 tüve) antigeene annuses 0,3 kuni 1,75 µg.
Here Eurican Herpes 205 was compared with no vaccination (controls). 
Siin Eurican Herpes 205-t teiste vaktsiinidega (kontrollrühmadega) ei võrreldud.
When injected, this small exposure helps the dog's immune system to synthesize antibodies against the canine herpes virus and to neutralize it. Once vaccinated, bitches will, through colostrum, give those antibodies to puppies. 
Pärast süstimist aitab see väike annus koera immuunsüsteemil sünteesida koerte herpesviiruse vastaseid antikehi ja viirust neutraliseerida.
The first injection is given either when the bitch is on heat or 7 -10 days after the date of mating. 
Esimene süst tehakse inna ajal või 7-10 päeva pärast paaritust.
They recommended that Eurican Herpes 205 should be given a marketing authorisation. 
Eurican Herpes 205-le soovitati anda müügiluba.
Eurican Herpes 205 is given as two 1 ml subcutaneous (under the skin) doses. 
Eurican Herpes 205-t manustatakse kahe 1 ml subkutaanse annusena (naha alla).
Eurican Herpes 205 is used to immunise pregnant bitches to prevent mortality, clinical signs and lesions in puppies caused by canine herpes virus infections acquired in the first few days of life. 
Eurican Herpes 205-t kasutatakse tiinete emaste koerte immuniseerimiseks koerte herpesviirusinfektsioonidest põhjustatud surma vastu ning esimestel elupäevadel omandatud nimetatud viirusest tingitud kliiniliste nähtude ja kahjustuste ennetamiseks kutsikatel.
The second study was carried out to show the protection of puppies from vaccinated bitches from canine herpe svirus. 
Teises uuringus vaadeldi vaktsineeritud emaste koerte kutsikate kaitstust koerte herpesviiruse vastu.
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Eurican Herpes 205 are greater than any risks to immunise healthy bitches against canine herpes virus. 
Veterinaarravimite komitee otsustas, et Eurican Herpes 205 kasulikkus selle kasutamisel tervete emaste koerte immuniseerimiseks koerte herpesviiruse vastu on suurem kui sellega kaasnevad riskid.
The benefitrisk balance may be found in module 6 of this EPAR. 
Ravimi kasulikkuse ja riski suhte leiate käesoleva Euroopa avaliku hindamisaruande 6. jaotisest.
Other information about Eurican Herpes 205: 
Muu teave Eurican Herpes 205 kohta
The injection of Eurican Herpes 205 may cause temporary oedema (fluid under the skin) at the injection site in up to 10% of animals. 
Eurican Herpes 205 süstimine võib tekitada kuni 10%-l loomadest süstekohal ajutise turse (nahaaluse vedelikukogumi).
Eurican Herpes 205 contains small amounts of canine herpes virus antigens. 
Eurican Herpes 205 sisaldab vähesel hulgal koerte herpesviiruse antigeene.
Eurican Herpes 205 showed good protection from canine herpes virus. 
Tõendati, et Eurican Herpes 205 kaitseb hästi koerte herpesviiruse vastu.
How has the effectiveness of Eurican Herpes 205 been studied? 
Kuidas Eurican Herpes 205 efektiivsust uuriti?
Why has Eurican Herpes 205 been approved? 
Miks Eurican Herpes 205 heaks kiideti?
Eurican Herpes 205 is a powder and solvent that is made into an emulsion for injection. 
Eurican Herpes 205-t turustatakse pulbri ja lahustina, millest valmistatakse süsteemulsioon.
What is Eurican Herpes 205? 
Mis on Eurican Herpes 205?
How does Eurican Herpes 205 work? 
Kuidas Eurican Herpes 205 toimib?
What is Eurican Herpes 205 used for? 
Milleks Eurican Herpes 205-t kasutatakse?
What are the side effects of Eurican Herpes 205? 
Millised on Eurican Herpes 205 kõrvaltoimed?
What benefit has Eurican Herpes 205 shown during the studies? 
Milles seisneb uuringute põhjal Eurican Herpes 205 kasulikkus?
09 October 2013 
09. oktoober 2013
The European Commission issued a decision on this opinion on 09 October 2013. 
Euroopa Komisjon tegi sellel arvamusel põhineva otsuse 09. oktoobril 2013.
The company wanted the authorisation to be recognised in Belgium, France, Germany, Luxembourg, Malta, Netherlands, Sweden and United Kingdom (the ‘concerned Member States'). 
Ettevõte soovis, et müügiluba tunnustataks Belgias, Luksemburgis, Madalmaades, Maltal, Prantsusmaal, Rootsis, Saksamaal ja Ühendkuningriigis (asjaomased liikmesriigid).
Committee for Human Medicinal Products. 
1 Inimravimite komitee.
Two medicines are bioequivalent if they produce the same levels of the active substance in the body. 
Kaks ravimit on bioekvivalentsed, kui mõlemad tekitavad organismis sama toimeainesisalduse.
Sandoz A/S submitted Methylphenidate Sandoz for mutual recognition on the basis of the initial authorisation granted by Denmark on 29 March 2012 and also valid through a decentralised procedure in Cyprus, Finland, Poland, Portugal and Spain, as well as Iceland and Norway. 
Sandoz A/S esitas ravimi Methylphenidate Sandoz vastastikuse tunnustamise taotluse, võttes aluseks Taanis 29. märtsil 2012 antud esialgse müügiloa, mis kehtis detsentraliseeritud menetluse kaudu ka Hispaanias, Küprosel, Poolas, Portugalis ja Soomes, samuti Islandil ja Norras.
What is Methylphenidate Sandoz? 
Mis on Methylphenidate Sandoz?
However, the Member States were not able to reach an agreement and the Danish medicines regulatory agency referred the matter to the CHMP for arbitration on 21 December 2012. 
Liikmesriigid ei jõudnud aga kokkuleppele ning 21. detsembril 2012 tegi Taani ravimiamet inimravimite komiteele vahekohtumenetluse algatamise esildise.
As the product information states that the tablet can be taken with or without food, a bioequivalence study in fed conditions was required to grant the marketing authorisation. 
Kuivõrd ravimiteabes öeldakse, et tableti tohib võtta koos toiduga või ilma, oli müügiloa taotlemiseks vaja teha ka täis kõhu tingimuste bioekvivalentsusuuring.
On 25 July 2013, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Methylphenidate Sandoz. 
Euroopa Ravimiamet (EMA) lõpetas 25. juulil 2013 vahekohtumenetluse, mis algatati pärast seda, kui Euroopa Liidu liikmesriigid ei jõudnud kokkuleppele ravimi Methylphenidate Sandoz heakskiitmises.
Why was Methylphenidate Sandoz reviewed? 
Miks ravimi Methylphenidate Sandoz andmed uuesti läbi vaadati?
The grounds for the referral were objections raised by Germany and the Netherlands who considered that the bioequivalence study carried out under fed conditions did not show that Methylphenidate Sandoz was bioequivalent for the immediate-release phase to its reference product. 
Esildise põhjus oli Saksamaa ja Madalmaade vastuväited, et täis kõhu tingimuste bioekvivalentsusuuring ei näidanud, et Methylphenidate Sandoz oleks võrdlusravimiga toimeainet kohe vabastavas faasis bioekvivalentne.
It has been available since the 1950s as both immediate-release tablets and capsules, which release methylphenidate straight away, and as modified-release tablets that release some or all of the active substance more slowly over several hours. 
Metüülfenidaati on turustatud alates 1950. aastatest nii toimeainet kiiresti vabastavate tablettidena kui ka kohe vabastavate kapslitena ning modifitseeritult vabastavate tablettidena, millest osa toimeainet või kogu toimeaine vabaneb aeglasemalt mitme tunni vältel.
It is available as a modified-release tablet, which releases some of the active substance immediately (the ‘immediate-release phase') and the rest over several hours. 
Concertat turustatakse toimeainet modifitseeritult vabastavate tablettidena, millest osa toimeainet vabaneb kohe (toimeainet kohe vabastav faas) ja ülejäänud toimeaine vabaneb aeglaselt mitme tunni vältel.
Questions & Answers: Positions on specific questions addressed to the pharmacokinetics working party. 
Teabedokument: farmakokineetika töörühma vastused küsimustele.
The Committee also noted that the studies were performed by the applicant before the publication of recent updated guidance1 for products of this type. 
Inimravimite komitee märkis ka, et müügiloa taotleja oli uuringud korraldanud enne seda tüüpi ravimite bioekvivalentsuse tõendamise suuniste uuendatud versiooni1 avaldamist.
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the failure to show bioequivalence between Methylphenidate Sandoz and its reference medicine in the immediate-release phase under fed conditions were due to differences between patients in the effects of a high-fat meal on the way medicines are handled by the body, and not to differences between the formulations of the two medicinal products, and that bioequivalence to the reference medicinal product has been shown. 
Tuginedes olemasolevate andmete hindamisele ja komiteesisesele teaduslikule arutelule, järeldas inimravimite komitee, et Methylphenidate Sandozi ja selle võrdlusravimi bioekvivalentsust toimeainet kohe vabastavas faasis täis kõhu tingimustes ei suudetud tõendada mitte kahe ravimvormi erinevuse tõttu, vaid patsientidevaheliste ja füsioloogiliste tingimuste varieeruvuse tõttu pärast suure rasvasisaldusega toidu söömist, seega on bioekvivalentsus võrdlusravimiga siiski tõendatud.
Methylphenidate Sandoz is a generic medicine based on a ‘reference medicine', Concerta, which is authorised in all the EU Member States. 
Methylphenidate Sandoz on geneeriline ravim, mille võrdlusravimil Concerta on müügiluba Euroopa Liidu kõigis liikmesriikides.
Questions and answers on Methylphenidate Sandoz (methylphenidate hydrochloride, prolonged-release tablet 18, 36 and 54 mg) EMA/444197/2013 rev.1 
Ravimi Methylphenidate Sandoz teave (metüülfenidaatvesinikkloriid, 18 mg, 36 mg ja 54 mg toimeainet prolongeeritult vabastavad tabletid) EMA/444197/2013 rev.1
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Methylphenidate Sandoz outweigh its risks, and the marketing authorisation granted in Denmark can be recognised in other Member States of the EU. 
EMA inimravimite komitee järeldas, et ravimi Methylphenidate Sandoz kasulikkus on suurem kui sellega kaasnevad riskid ja Taanis antud müügiluba tohib tunnustada Euroopa Liidu teistes liikmesriikides.
Requirements for demonstration of bioequivalence for generics of biphasic modified release formulations for oral use. 
Geneeriliste kahefaasiliste toimeainet modifitseeritult vabastavate suukaudsete ravimvormide bioekvivalentsuse tõendamise nõuded.
The CHMP therefore concluded that the benefits of Methylphenidate Sandoz outweigh its risks and recommended that the marketing authorisation be granted in the concerned Member States. 
Seetõttu järeldas inimravimite komitee, et ravimi Methylphenidate Sandoz kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas asjaomastes liikmesriikides anda ravimi müügiloa.
Methylphenidate belongs to a group of medicines called ‘psychostimulants' and is thought to work by enhancing the activity of areas of the brain that control attention and concentration. 
Metüülfenidaadi oletatav toimemehhanism on tähelepanu ja kontsentreerumist juhtivate ajupiirkondade aktiivsuse suurendamine.
Questions and answers on Methylphenidate Sandoz (methylphenidate hydrochloride, prolonged-release tablet 18, 36 and 54 mg) 
Ravimi Methylphenidate Sandoz teave (metüülfenidaatvesinikkloriid, 18 mg, 36 mg ja 54 mg toimeainet prolongeeritult vabastavad tabletid)
Methylphenidate is a medicine that is used to treat children aged between 6 and 18 years of age who have ADHD (attention deficit/hyperactivity disorder), a condition in which children show a persistent inability to concentrate, hyperactivity and impulsive behaviour. 
ADHD korral esineb lastel püsiv keskendumisvõimetus, hüperaktiivsus ja impulsiivne käitumine.
Further information on Ferriprox can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/ferriprox. 
Lisateave Ferriproxi kohta on ameti veebilehel: ema.europa.eu/en/medicines/human/EPAR/ferriprox.
Over time, the excess iron can damage important organs such as the heart and liver. 
Liigne raud võib aja jooksul kahjustada tähtsaid elundeid, näiteks südant ja maksa.
What measures are being taken to ensure the safe and effective use of Ferriprox? 
Mis meetmed võetakse, et tagada Ferriproxi ohutu ja efektiivne kasutamine?
Removing iron in this way helps to correct the iron overload and prevent damage from excess iron. 
Raua sellisel viisil eemaldamine aitab raualiigsust korrigeerida ja ennetada liigsest rauast põhjustatud kahjustust.
Ferriprox received a marketing authorisation valid throughout the EU on 25 August 1999. 
Ferriprox on saanud müügiloa, mis kehtib kogu ELis, 25. augustil 1999.
The European Medicines Agency decided that Ferriprox's benefits are greater than its risks and it can be authorised for use in the EU. 
Euroopa Ravimiamet otsustas, et Ferriproxi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
It is available as tablets (500 and 1,000 mg) and as an oral solution (100 mg/ml). 
Ferriproxi turustatakse tablettidena (500 ja 1000 mg) ja suukaudse lahusena (100 mg/ml).
The doctor may interrupt treatment if iron levels get too low. 
Arst võib ravi katkestada, kui rauasisaldus muutub liiga väikeseks.
The total dose for the whole day should be less than 100 mg per kilogram body weight. 
Ööpäevane koguannus peab olema väiksem kui 100 mg kehamassi kg kohta.
Patients should tell their doctor immediately if they have symptoms of an infection, such as fever, sore throat and flu-like symptoms. 
Patsiendid peavad kohe arsti poole pöörduma, kui neil tekivad infektsiooni sümptomid, nt palavik, kurguvalu ja gripilaadsed sümptomid.
Ferriprox (deferiprone) 
Ferriprox (deferiproon)
• on its own, when standard iron chelator treatment cannot be used or does not work well enough; 
• ainuravimina, kui tavaravi rauakelaatoriga on vastunäidustatud või ei toimi piisavalt hästi;
As for all medicines, data on the use of Ferriprox are continuously monitored. 
Nagu kõigi ravimite puhul, tehakse Ferriproxi kasutamise kohta pidevat järelevalvet.
• in combination with another iron chelator, when treatment with one iron chelator on its own does not work or when iron levels need to be rapidly or intensively corrected to prevent or treat lifethreatening conditions (mainly affecting the heart). 
• kombinatsioonis teise rauakelaatoriga, kui ravi rauakelaatoriga ainuravimina ei toimi või kui rauasisaldust tuleb kiiresti või intensiivselt korrigeerida, et ennetada või ravida eluohtlikke
The doctor may adjust the dose of Ferriprox according to how well the patient's iron levels are being controlled, which should be measured every 2 to 3 months with blood tests. 
Arst võib Ferriproxi annust kohandada vastavalt sellele, kui hästi on patsiendil korrigeeritud rauasisaldus, mida tuleb määrata vereanalüüsidega iga 2-3 kuu järel.
Side effects reported with Ferriprox are carefully evaluated and any necessary action taken to protect patients. 
Ferriproxi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
The average blood ferritin levels were similar in the two treatment groups. 
Vere keskmine ferritiinisisaldus oli mõlemas ravirühmas sarnane.
Other information about Ferriprox 
Muu teave Ferriproxi kohta
The main measure of effectiveness was the change in the levels of ferritin in the blood. 
Efektiivsuse põhinäitaja oli ferritiinisisalduse muutus patsientide veres.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ferriprox have also been included in the summary of product characteristics and the package leaflet. 
Ferriproxi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
The usual dose of Ferriprox is 25 mg per kilogram body weight three times a day. 
Ferriproxi soovitatav annus on 25 mg kehamassi kg kohta 3 korda ööpäevas.
If the patient gets an infection, treatment with Ferriprox should be temporarily stopped and the neutrophil count checked more often. 
Kui patsiendil tekib infektsioon, tuleb ravi Ferriproxiga ajutiselt katkestada ning neutrofiilide sisaldust sagedamini kontrollida.
The company that markets Ferriprox must supply a reminder card for patients or their carers about the importance of regular tests for neutrophil counts, the need to watch out for symptoms of infection and for women to avoid becoming pregnant during treatment with Ferriprox. 
Ferriproxi turustaja peab andma patsientidele või nende hooldajatele hoiatuskaardi neutrofiilide sisalduse regulaarse kontrollimise olulisuse kohta, vajaduse kohta jälgida infektsioonisümptomite teket ning naistele vajaduse kohta vältida rasestumist ravi ajal Ferriproxiga.
What is Ferriprox and what is it used for? 
Mis on Ferriprox ja milleks seda kasutatakse?
For more information about using Ferriprox, see the package leaflet or contact your doctor or pharmacist. 
Lisateavet Ferriproxi kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
The most common side effects with Ferriprox (which may affect more than 1 in 10 people) are redbrown urine (showing that iron is being removed through the urine), nausea (feeling sick), abdominal pain (stomach ache) and vomiting. 
Ferriproxi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on punakaspruun uriin (mis näitab raua eritumist), iiveldus, kõhuvalu ja oksendamine.
When taking Ferriprox, the patient's neutrophil count should be checked regularly (every week in the first year then less frequently). 
Kui patsient võtab Ferriproxi, tuleb tal regulaarselt kontrollida neutrofiilide sisaldust (esimesel raviaastal iga nädal, seejärel harvem).
Why is Ferriprox authorised in the EU? 
Miks Ferriprox ELis heaks kiideti?
Ferriprox was studied in 247 patients with thalassaemia major, aged over 6 years. 
Ferriproxi uuriti 247 üle 6-aastasel raske talassemiaga patsiendil.
There were too few patients in the study to prove whether such a schedule is as effective as deferoxamine on its own. 
Uuringus ei osalenud piisavalt patsiente, tõestamaks, et see raviskeem on sama efektiivne kui deferoksamiin ainuravimina.
With repeated transfusions, the iron builds up because the body does not have a natural way of removing excess iron. 
Korduvülekannete tulemusel ladestub raud organismis, sest organismis puudub raua eemaldamise looduslik mehhanism.
Ferriprox must also not be used with medicines that might cause neutropenia or agranulocytosis. 
Ferriproxi ei tohi kasutada ka koos ravimitega, mis võivad põhjustada neutropeeniat või agranulotsütoosi.
In another study involving 60 patients treated over 12 months, a combination of Ferriprox and deferoxamine (Ferriprox for 5 days plus deferoxamine for 2 days each week) was compared with deferoxamine on its own. 
Teises uuringus, milles osales 60 patsienti, keda raviti 12 kuud, võrreldi Ferriproxi ja deferoksamiini kombinatsiooni (iga nädal 5 päeva Ferriproxi ja 2 päeva deferoksamiini) deferoksamiiniga ainuravimina.
Less common but more serious side effects are agranulocytosis (very low levels of granulocytes, a type of white blood cell) and neutropenia (low levels of neutrophils, a type of white blood cell that fights infections). 
Harvem esinevad, kuid raskemad kõrvalnähud on agranulotsütoos (teatud valgeliblede, granulotsüütide väga väike sisaldus) ja neutropeenia (teatud valgeliblede, neutrofiilide väike sisaldus).
Ferriprox contains the active substance deferiprone. 
Ferriprox sisaldab toimeainena deferiprooni.
For the full list of restrictions and side effects of Ferriprox, see the package leaflet. 
Ferriproxi kohta teatatud piirangute ja kõrvalnähtude täielik loetelu on pakendi infolehel.
This is an inherited disease in which patients are unable to make enough haemoglobin, the protein found in red blood cells that carries oxygen around the body. 
Talasseemia on pärilik haigus, mille korral patsiendil ei teki piisavalt hemoglobiini (vere punaliblede valk, mis kannab hapnikku organismis laiali).
In addition, published studies on Ferriprox together with deferoxamine reported greater reductions in blood ferritin levels when both medicines were used in combination compared with using either medicine on its own. 
Lisaks märgiti Ferriproxi ja deferoksamiini kooskasutamise kohta avaldatud uuringutes vere ferritiinisisalduse suuremat vähenemist mõlema ravimi kombinatsiooniga kui nende kasutamisel ainuravimitena.
Ferriprox must not be used in women who are pregnant or breastfeeding. 
Ferriproxi ei tohi kasutada raseduse või imetamise ajal.
Ferriprox is an ‘iron chelator' (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major. 
Ferriprox on rauakelaator (st rauaga seonduv aine) ja seda kasutatakse raualiigsuse (organismi liigse rauasisalduse) raviks raske talasseemiaga patsientidel.
Transfused red cells bring iron into the body. 
Koos ülekantavate punalibledega saab organism ka rauda.
Ferriprox must not be used in people who have had neutropenia repeatedly or agranulocytosis. 
Ferriproxi ei tohi kasutada patsiendid, kellel on korduvalt esinenud neutropeeniat või agranulotsütoosi.
How does Ferriprox work? 
Kuidas Ferriprox toimib?
What are the risks associated with Ferriprox? 
Mis riskid Ferriproxiga kaasnevad?
How is Ferriprox used? 
Kuidas Ferriproxi kasutatakse?
However, the average iron concentration in the liver of Ferriprox-treated patients seemed to increase more than in deferoxamine-treated patients. 
Ferriproxiga ravitud patsientidel näis keskmine rauakontsentratsioon maksas siiski suurenevat rohkem kui deferoksamiiniga ravitud patsientidel.
The main study involving 71 patients compared Ferriprox with deferoxamine, another iron chelator, over 2 years. 
Põhiuuringus, milles osales 71 patsienti, võrreldi 2 aasta jooksul Ferriproxi deferoksamiiniga (samuti rauakelaator).
Ferriprox is used: 
Ferriproxi kasutatakse järgmiselt:
Blood ferritin levels were reduced to the same extent in patients treated with the combination as with deferoxamine on its own. 
Vere ferritiinisisaldus vähenes kombinatsioonraviga patsientidel samal määral kui neil, kes said deferoksamiini ainuravimina.
An overview of Ferriprox and why it is authorised in the EU 
Ülevaade ravimist Ferriprox ja ELis müügiloa väljastamise põhjendus